Claims for Patent: 7,795,033

Summary for Patent: 7,795,033

Title:	Methods to predict the outcome of treatment with antidepressant medication
Abstract:	The invention provides a method for determining the outcome of treatment with an antidepressant medication in a patient. In particular, the invention provides a method of screening patients to identify those patients with a decreased risk of non-response to treatment with antidepressant medication by obtaining a sample of genetic material from the patients, and then assaying the sample for the presence of a genotype which is associated with a decreased risk of non-response to treatment with antidepressant medication. The genotype is characterized by a polymorphism in the genes HTR2A, GRIK4, BCL2, and a combination thereof.
Inventor(s):	McMahon; Francis J. (Bethesda, MD), Laje; Gonzalo E. (Potomac, MD), Paddock; Silvia (Solna, SE), Manji; Husseini K. (Titusville, NJ), Rush; A. John (Singapore, SG), Wilson; Alexander F. (Phoenix, MD)
Assignee:	The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (Austin, TX) Board of Regents, The University of Texas System (N/A)
Application Number:	12/051,494
Patent Claims:	1. A method of predicting the outcome of treatment with antidepressant medication in a patient comprising: (a) obtaining a sample of genetic material from the patient; (b) assaying the sample for the presence of a genotype in the patient which is associated with the outcome of treatment with antidepressant medication; and (c) predicting the outcome of treatment with antidepressant medication in the patient based on the presence of the genotype in the sample, wherein the genotype is characterized by a polymorphism in a gene having at least one marker, wherein the gene is selected from the group consisting of 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A); glutamine receptor, ionotropic, kainate 4 (GRIK4); B-cell leukemia/lymphoma 2 (BCL2); and a combination thereof, and wherein when the selected gene is HTR2A, the polymorphism is located within intron 2 of HTR2A, and the marker is selected from the group consisting of rs7997012, rs1928040, rs7333412, rs977003 and rs1745837, and/or the polymorphism is located within the 3' untranslated region of HTR2A. 2. The method of claim 1, wherein assaying comprises detecting the polymorphism by allele specific hybridization, allele specific oligonucleotide ligation, primer extension, minisequencing, mass spectroscopy, heteroduplex analysis, single strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), oligonucleotide microarray analysis, temperature gradient gel electrophoresis (TGGE), and combinations thereof. 3. The method of claim 1, wherein the gene is HTR2A. 4. The method of claim 3, wherein the polymorphism is within intron 2 of HTR2A. 5. The method of claim 3, wherein the polymorphism is within the 3' untranslated region of HTR2A. 6. The method of claim 1, wherein the gene is GRIK4. 7. The method of claim 6, wherein the polymorphism is within intron 1 of GRIK4. 8. The method of claim 1, wherein the gene is BCL2. 9. The method of claim 8, wherein the polymorphism is within intron 2 of BCL2. 10. The method of claim 1, wherein the antidepressant medication is a selective serotonin reuptake inhibitor. 11. The method of claim 10, wherein the selective serotonin reuptake inhibitor is citalopram. 12. A method of screening patients to identify those patients with a decreased risk of non-response to treatment with antidepressant medication comprising: (a) obtaining a sample of genetic material from the patients; (b) assaying the sample for the presence of a genotype in the patients which is associated with a decreased risk of non-response to treatment with antidepressant medication; and (c) identifying a decreased risk of non-response to treatment with antidepressant medication in the patients based on the presence of the genotype in the sample, wherein the genotype is characterized by a polymorphism in a gene having at least one marker, wherein the gene is selected from the group consisting of 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A); glutamine receptor, ionotropic, kainate 4 (GRIK4); B-cell leukemia/lymphoma 2 (BCL2); and combinations thereof, and wherein when the selected gene is HTR2A, the polymorphism is located within intron 2 of HTR2A, and the marker is selected from the group consisting of rs7997012, rs1928040, rs7333412, rs977003 and rs1745837, and/or the polymorphism is located within the 3' untranslated region of HTR2A. 13. The method of claim 12, wherein assaying comprises detecting the polymorphism by allele specific hybridization, allele specific oligonucleotide ligation, primer extension, minisequencing, mass spectroscopy, heteroduplex analysis, single strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), oligonucleotide microarray analysis, temperature gradient gel electrophoresis (TGGE), and combinations thereof. 14. The method claim 12, wherein the gene is HTR2A. 15. The method of claim 14, wherein the polymorphism is within intron 2 of HTR2A. 16. The method of claim 14, wherein the polymorphism is within the 3' untranslated region of HTR2A. 17. The method of claim 12, wherein the gene is GRIK4. 18. The method of claim 17, wherein the polymorphism is within intron 1 of GRIK4. 19. The method of claim 12, wherein the gene is BCL2. 20. The method of claim 19, wherein the polymorphism is within intron 2 of BCL2. 21. The method of claim 12, wherein assaying for the presence of the genotype comprises detecting the presence of at least one of SEQ ID NOs: 1-18 and 36-39. 22. The method of claim 12, further comprising assaying for the presence of a genotype in the patients which is associated with a decreased risk of non-response to treatment with antidepressant medication, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamate receptor, ionotropic, N-methyl D-aspartate (GRIN) 2A; GRIK1; and combinations thereof. 23. The method of claim 22, wherein assaying for the presence of the genotype comprises detecting the presence of at least one of SEQ ID NOs: 19-35. 24. The method of claim 12, wherein the antidepressant medication is a selective serotonin reuptake inhibitor. 25. The method of claim 24, wherein the selective serotonin reuptake inhibitor is citalopram.

Details for Patent 7,795,033

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2027-03-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2027-03-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2027-03-19